Vanguard Capital Management’s Pelthos Therapeutics PTHS Stock Holding History
Bought
Maintained
Sold
Other funds holding PTHS
ACM
DMKJ
Vanguard Capital Management's PTHS Position: Q3 2026 in Review
Vanguard Capital Management reduced its Pelthos Therapeutics (PTHS) stake by 1.9% in Q3 2026, selling an estimated $46.3K and leaving 95,316 shares worth $2M. The position accounts for ﹤0.01% of the portfolio, ranked #3368.
Vanguard Capital Management first reported a position in PTHS in Q1 2026 and has held it in 3 quarters since. The position peaked at $2.75M in Q2 2026. 29 funds tracked by Wall St. Rank hold PTHS as of Q3 2026.
- Vanguard Capital Management held 95,316 shares of Pelthos Therapeutics worth $2M as of Q3 2026.
- Vanguard Capital Management sold 1,818 Pelthos Therapeutics shares in Q3 2026, an estimated $46.3K.
- Pelthos Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3368 holding.
- Vanguard Capital Management first reported a position in Pelthos Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Pelthos Therapeutics position peaked at $2.75M in Q2 2026.
- 29 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.